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Abstract
The objective of this study was to analyze the im-
pact of vaccination against Streptococcus pneu-
moniae on the morbidity and mortality from 
pneumococcal meningitis in children ≤ 2 years 
in Brazil, from 2007 to 2012. This is a descriptive 
study and ecological analysis using data from the 
Information System on Notifiable Diseases. Pre-
vaccination (2007-2009) and post-vaccination 
(2011-2012) periods were defined to compare in-
cidence rates and mortality. A total of 1,311 cases 
and 430 deaths were reported during the study 
period. Incidence decreased from 3.70/100,000 in 
2007 to 1.84/100,000 in 2012, and mortality de-
creased from 1.30/100,000 to 0.40/100,000, or 50% 
and 69% respectively, with the greatest impact in 
the 6-11 month age group. This decrease in Pneu-
mococcal meningitis morbidity and mortality 
rates two years after introduction of the 10-va-
lent pneumococcal conjugate vaccine suggests its 
effectiveness.
Streptococcus pneumoniae; Meningitis; Vaccines
Resumo
O objetivo deste trabalho foi analisar o impacto da 
vacinação contra o Streptococcus pneumoniae 
na morbidade e mortalidade por meningite pneu-
mocócica em crianças ≤ 2 anos, no Brasil, entre 
2007-2012. Este é um estudo descritivo com análi-
se ecológica, utilizando dados do Sistema de Infor-
mação de Agravos de Notificação. Foram definidos 
os períodos pré-vacinal (2007-2009) e pós-vacinal 
(2011-2012) para comparar as taxas de incidência 
e mortalidade. Foram identificados 1.311 casos e 
430 óbitos no período do estudo. A taxa de incidên-
cia diminuiu de 3,70/100.000 no ano de 2007 para 
1,84/100.000 em 2012, e a mortalidade reduziu 
de 1,30/100.000 para 0,40/100.000, o que significa 
uma redução de 50% e 69%, respectivamente, com 
maior impacto identificado na faixa etária de 6 a 
11 meses. Os resultados indicam uma diminuição 
nos indicadores de morbidade e mortalidade de 
meningite pneumocócica, observados dois anos 
após a introdução da vacina pneumocócica con-
jugada 10-valente, sugerindo sua efetividade.
Streptococcus pneumoniae; Meningite; Vacinas
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Introduction
Streptococcus pneumoniae (pneumococcus) is 
one of the main etiological agents of bacterial 
pneumonia, septicemia, and meningitis in chil-
dren worldwide, accounting for approximately 
800 thousand deaths year in children younger 
than 5 years 1,2,3. In Brazil, pneumococcal men-
ingitis is the second leading cause of bacterial 
meningitis 4, especially in infants younger than 
1 year 5. According to data from the SINAN da-
tabase (Information System on Notifiable Dis-
eases), the mean annual incidence rates in 2001 
and 2010 in children younger than 5 years and 
younger than 1 year were 1.09 and 8.62 cas-
es/100,000 inhabitants, and the mean case-fa-
tality rates were 33.6% and 31.3%, respectively. 
Bacterial meningitis has been a disease of com-
pulsory notification in Brazil since 1975.
Advances in the immunogenicity and effi-
cacy of anti-pneumococcal vaccines introduced 
since 1983 have highlighted their importance 
in the control and prevention of pneumococcal 
diseases as the leading cause of vaccine-pre-
ventable deaths 6. Global performance against 
invasive pneumococcal disease were considered 
satisfactory using the first pneumococcal conju-
gate vaccine, including seven serotypes (PCV7), 
demonstrating 80% efficacy against invasive 
pneumococcal disease caused by the seven vac-
cine serotypes worldwide 7. In Australia, Europe, 
and North America, the impact of PCV7 on inva-
sive pneumococcal disease was a reduction that 
varied from 17% in Spain 8 to 80% in the United 
States 9, with a mean decline of 45% 10. Reduc-
tions in invasive pneumococcal disease caused 
by the seven serotypes in all age groups and as-
sociated with childhood vaccination varied from 
1% in the Netherlands 11 to 94% in the United 
States 12, with a mean reduction of 65.5% 10.
In Brazil, 10-valent pneumococcal conjugate 
vaccine (PCV10) was introduced into the child-
hood vaccination schedule of the National Im-
munization Program, Ministry of Health (PNI/
MS) in 2010, with the recommendation of three 
doses, at two, four, and six months of age, with 
a booster between 12 and 15 months 13. The ap-
proval of PCV10 was initially based on studies 
of PCV7, as recommended by the World Health 
Organization (WHO) 14. Even with the declin-
ing trend in pneumococcal meningitis in recent 
years in Brazil 15, the introduction of PCV10 raises 
further prospects for controlling pneumococcal 
disease, with Brazil as the forerunner in imple-
menting this vaccine in its Public Health System. 
In this scenario, performance analyses of 
PCV10 are essential for assessing the interven-
tion’s impact. The current study’s objectives were 
to describe cases of pneumococcal meningitis 
in children up to 2 years of age and to compare 
the incidence and mortality rates in the pre- and 
post-implementation periods for the PCV10 vac-
cine in Brazil, thus contributing knowledge to 
support meningitis surveillance and strengthen 
the country’s public health policies.
Method
A descriptive study of cases of pneumococcal 
meningitis was performed, in addition to an eco-
logical analysis of incidence and mortality rates 
for the disease in the immediate pre- and post-
implementation periods for PCV10. Cases of 
pneumococcal meningitis included in the study 
were in children 2 years or younger, recorded in 
the SINAN database and confirmed by a specific 
laboratory criterion, which included isolation of 
S. pneumoniae in culture, latex agglutination re-
action, or polymerase chain reaction (PCR). 
The introduction of PCV10 vaccine varied be-
tween the States of Brazil in 2010, so that year was 
excluded from the statistical analyses. Thus, the 
pre-vaccination period was defined as the three 
years prior to introduction of the vaccine (2007-
2009), and the post-vaccination period included 
the years 2011 and 2012. 
Calculation of the incidence and mortal-
ity rates from pneumococcal meningitis used 
population estimates reported by the Brazilian 
Institute of Geography and Statistics (IBGE – 
http://www.sidra.ibge.gov.br/bda/tabela/listabl.
asp?c=1552&z=cdo=7, accessed on 22/Jan/2014; 
http://www.ibge.gov.br/home/estatistica/popu 
lacao/trabalhoerendimento/pnad2012/micro 
dados.shtm, accessed on 22/Jan/2014). Stratifi-
cation of the population of infants under 1 year 
(reported by IBGE) into two groups (younger and 
older than six months) used the proportion of 
infants under six months according to the da-
tabase of the Information System on Live Births 
(SINASC) for each year included in the study 
(http://tabnet.datasus.gov.br/cgi/sinasc/dados/
nov_indice.htm, accessed on 22/Jan/2014).
Cases of pneumococcal meningitis were de-
scribed by age group, gender, signs and symp-
toms, confirmation criterion, evolution, and 
State and geographic region of residence, as re-
corded on the notification form. Data on vaccine 
status were not included, since they showed un-
satisfactory completeness.
The study was approved by the Ethics Re-
search Committee of the School of Health Sci-
ences, University of Brasília (CEP/FS-UNB, re-
view n. 171/711). 
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Results
The study included 1,311 cases of pneumococcal 
meningitis in children up to 2 years of age and re-
ported in the SINAN database from 2007 to 2012. 
Seventy-nine cases (5%) were excluded due to 
lack of specific laboratory confirmation. The 269 
cases (16%) reported in 2010 were also excluded 
from the analysis since PCV10 was introduced 
that year. 
Of the 1,311 cases of pneumococcal menin-
gitis, 60% (n = 785) were in boys. The age group 
younger than one year accounted for the high-
est proportion of cases, concentrated in infants 
younger than six months in the post-vaccination 
period (Table 1).
The signs and symptoms described in all the 
study years were fever, vomiting, and seizures. 
As for confirmation, 69% (n = 906) of the cases 
were confirmed by culture, 27% (n = 357) by latex 
agglutination, and 4% (n = 48) by PCR. Culture 
was the principal confirmation criterion in all the 
study years, and there was an increase in cases 
confirmed by latex and PCR in the post-vaccina-
tion period (Table 1). 
Approximately 30% of cases evolved to death 
each year during the study period, but in the sec-
ond year of the post-vaccination period this pro-
portion decreased to 22% (Table 1).
The highest proportions of cases in the entire 
study period were in the Southeast and South re-
gions of Brazil, with 59% and 16%, respectively. 
The highest incidence rates were also seen in 
these regions. Meanwhile, the largest reductions 
in these rates when comparing 2012 to 2007 were 
in the States of Minas Gerais and Santa Catarina, 
both with a decrease of 65% (Table 2).
Table 3 shows that proportionally, the larg-
est share of cases of pneumococcal meningitis 
occurred in the year 2007, with 30% of the cas-
es from the study period, a proportion that re-
mained relatively stable in 2008 and 2009. The 
two years of the post-vaccination period showed 
the lowest proportion of cases, with a decrease 
Table 1
Characteristics of cases of pneumococcal meningitis in the pre-vaccination period (2007-2009) and post-vaccination period 
(2011-2012) for PCV10. Brazil, 2007-2012.
Variables 2007 2008 2009 2011 2012
n % n % n % n % n %
Gender
Male 222 61.7 200 62.7 177 61.5 106 55.2 80 52.6
Female 138 38.3 119 37.3 111 38.5 86 44.8 72 47.4
Age group
< 1 year
< 6 months 136 37.8 98 30.7 98 34.0 111 57.8 78 51.3
≥ 6 months 124 34.4 120 37.6 109 37.8 39 20.3 29 19.1
1 year 74 20.6 75 23.5 53 18.4 21 10.9 26 17.1
2 years 26 7.2 26 8.2 28 9.7 21 10.9 19 12.5
Signs and symptoms
Fever 336 93.3 314 98.4 266 92.4 174 90.6 136 89.5
Vomiting 235 65.3 227 71.2 180 62.5 116 60.4 89 58.6
Seizures 164 45.6 154 48.3 119 41.3 76 39.6 61 40.1
Neck stiffness 138 38.3 137 42.9 117 40.6 58 30.2 52 34.2
Bulging fontanelle 116 32.2 89 27.9 82 28.5 58 30.2 50 32.9
Confirmatory criterion
Culture 277 76.9 222 69.6 205 71.2 114 59.4 88 57.9
Latex 80 22.2 87 27.3 73 25.3 68 35.4 49 32.2
PCR 3 0.8 10 3.1 10 3.5 10 5.2 15 9.9
Evolution
Cure 204 56.7 175 54.9 166 57.6 112 58.3 97 63.8
Death 127 35.3 106 33.2 97 33.7 65 33.9 33 21.7
Source: Information System on Notifiable Diseases (SINAN).
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of 14.6% in 2011 and 11.6% in 2012, accounting 
for a 58% reduction in the absolute number of 
cases when comparing 2012 to 2007. The high-
est incidence and mortality rates were in infants 
younger than one year throughout the study pe-
riod (Table 3).
The study showed a 50% reduction in the in-
cidence rate and 69% in the mortality rate from 
pneumococcal meningitis, comparing 2012 to 
2007. Children six months to one year of age 
showed the highest reductions in rates: 73% in 
incidence and 85% in mortality (Table 3).
The reductions in rates identified in this 
study two years after introduction of the PCV10 
were associated with vaccination coverage rates 
of 73% in 2011 and 89% in 2012, according to data 
from the PNI.
Discussion
After introduction of the 10-valent pneumo-
coccal conjugate vaccine in Brazil, there was 
a reduction in the number of cases and in the 
incidence of pneumococcal meningitis in chil-
dren younger than 2 years in 2012. There was 
an important reduction in the incidence rate 
for pneumococcal meningitis, especially in the 
second year post-vaccination when compared to 
the year 2007. The findings are similar to those 
in North America and Australia, where the inci-
dence of invasive pneumococcal disease, includ-
ing meningitis, declined by 56%-69% in children 
younger than 2 years, following introduction of 
PCV7 16,17,18,19,20,21,22,23. In Europe, in the same 
age group, the reduction was 82% after the intro-
duction of PCV7 24.
In Brazil, the highest incidence of pneumo-
coccal meningitis affects children younger than 
2 years 15. The largest decrease in the incidence 
rate for pneumococcal meningitis was in the 6-11 
month group. This corroborates a population-
based study in Brazil in 2012, relating invasive 
pneumococcal disease to pneumonias 25. An-
other finding was the reduction in the incidence 
of pneumococcal meningitis in the second year 
post-vaccination in infants younger than six 
months, similar to a study in the United States in 
2006, showing a 40% decrease in IPD in infants 
from birth to 90 days of age 21,25. 
This study’s results suggest the benefit of 
PCV10 in reducing the incidence of pneumococ-
cal meningitis, since the current literature refers 
to the impact of PCV7 used in other countries, 
with differences in the composition compared 
to PCV10, the latter with the addition of three 
more serotypes: 1, 5, and 7F. In Finland, results 
of a randomized clinical trial showed 92% and 
100% efficacy rates for PCV10 using vaccination 
schemes of 2+1 and 3+1 doses, respectively 26. In 
Quebec, PCV7 was replaced by PCV10 five years 
after the former was introduced, and the data 
show lower incidence of invasive pneumococ-
cal disease in children vaccinated with PCV10 
Table 2
Distribution of incidence rates (IR) * and mortality rates (MR) ** from pneumococcal meningitis in the Southeast and  
South regions and States of Brazil, 2007-2012.
Region/State 2007 2008 2009 2011 2012
IR MR IR MR IR MR IR MR IR MR
Southeast 5.65 2.08 4.88 1.73 4.78 1.84 3.93 1.42 2.99 0.69
MG 3.74 1.66 3.70 1.59 2.91 1.18 2.99 1.04 1.29 0.52
ES 5.53 1.66 1.72 1.15 4.06 1.16 3.37 1.35 2.67 1.34
RJ 5.86 3.15 4.83 1.96 5.44 3.68 5.81 2.66 3.62 0.82
SP 6.55 1.94 5.83 1.78 5.62 1.61 3.73 1.16 3.58 0.67
South 5.00 1.52 4.93 1.16 4.55 0.93 2.33 0.65 2.59 0.37
PR 5.73 2.55 5.77 1.77 4.36 0.69 2.29 0.23 3.64 0.91
SC 5.72 1.14 4.81 0.40 4.56 2.07 2.01 0.80 1.99 0.00
RS 3.80 0.67 4.09 0.96 4.76 0.50 2.58 1.03 1.80 0.00
Brazil 3.70 1.30 3.38 1.12 3.12 1.06 2.29 0.79 1.80 0.39
ES: Espírito Santo; MG: Minas Gerais; PR: Paraná; RJ: Rio de Janeiro; RS: Rio Grande do Sul; SC: Santa Catarina;  
SP: São Paulo. 
* Cases/100,000 inhabitants; 
** Deaths/100,000 inhabitants.
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Table 3
Characteristics of cases, annual proportions, incidence rates (IR) * and mortality rates, (MR) ** by age bracket for pneumococcal meningitis in the  
pre-vaccination period (2007-2009) and post-vaccination period (2011-2012) for PCV10. Brazil, 2007-2012.
Incidence/Age group Pre-vaccination Post-vaccination
2007 2008 2009 2011 2012 Total
n % IR N % IR n % IR n % IR n % IR n
< 1 year
< 6 months 136 26.1 8.92 98 18.8 6.47 98 18.8 6.71 111 21.3 8.46 78 15.0 5.88 521
≥ 6 months 124 29.5 7.46 120 28.5 7.65 109 25.9 7.02 39 9.3 2.74 29 6.9 2.02 421
1 year 74 29.7 2.28 75 30.1 2.39 53 21.3 1.73 21 8.4 0.77 26 10.4 0.95 249
2 years 26 21.7 0.79 26 21.7 0.81 28 23.3 0.89 21 17.5 0.76 19 15.8 0.68 120
Total 360 27.5 3.70 319 24.3 3.38 288 22.0 3.12 192 14.6 2.34 152 11.6 1.84 1311
Mortality/Age group Pre-vaccination Post-vaccination
2007 2008 2009 2011 2012 Total
n % MR N % MR n % MR n % MR n % MR n
< 1 year
< 6 months 40 16.5 2.62 111 45.7 1.31 36 14.8 2.46 39 16.0 2.97 17 7.0 1.28 243
≥ 6 months 54 35.1 3.25 39 25.3 0.36 42 27.3 2.71 12 7.8 0.84 7 4.5 0.49 154
1 year 25 33.3 0.77 21 28.0 0.32 14 18.7 0.46 9 12.0 0.33 6 8.0 0.22 75
2 years 8 18.2 0.24 21 47.7 0.94 6 13.6 0.19 6 13.6 0.22 3 6.8 0.11 44
Total 127 24.6 1.30 192 37.2 1.12 98 19.0 1.06 66 12.8 0.80 33 6.4 0.40 516
* Cases/100,000 inhabitants; 
** Deaths/100,000 inhabitants.
compared to PCV7 27. Importantly, the surveil-
lance data used in the current study did not iden-
tify the pneumococcal serotypes, which would 
have allowed assessing the vaccine’s specific im-
pact on the vaccine serotypes, thus representing 
a limitation to the study. The vaccine’s impact on 
the incidence of pneumococcal meningitis de-
pends on the prevalence of circulating serotypes 
in the population, vaccine coverage, and time 
since the vaccine’s introduction. Although this 
study did not aim to discuss State-by-State differ-
ences in incidence and mortality rates for pneu-
mococcal meningitis, it is important to mention 
that four States of Brazil (Distrito Federal, Ceará, 
Rio de Janeiro, and São Paulo) implemented vac-
cination schemes that differed from the guide-
lines of the PNI in terms of age at application of 
the doses. 
A study in Salvador, Brazil, estimated 77% 
coverage for PCV10 in children younger than 2 
years 28. In Goiânia, another study suggested 
80% coverage in children 28 days to 36 months 
of age 29. The reductions in the rates identified 
in this study two years after the introduction 
of PCV10 can be attributed to introduction of 
the vaccine, corroborating a study in the United 
States that reported a 64% decline in the inci-
dence of pneumococcal meningitis in children 
younger than 2 years, five years after the intro-
duction of PCV7 23. 
According to studies in France, England, and 
Wales, two years after the introduction of PCV7 
and with vaccine coverage of 75% or higher, there 
was a 30%-65% reduction in the incidence of in-
vasive pneumococcal disease from all serotypes. 
Just one year after vaccination, Germany, Nor-
way, and Denmark reported a 45-57% decline in 
invasive pneumococcal disease. Thus, the reduc-
tion in Europe was systematically lower than in 
the United States, where the incidence of inva-
sive pneumococcal disease in children younger 
than 2 years decreased 69% only one year after 
introduction of the vaccine 16 and 76% in children 
younger than 5 years, seven years after introduc-
tion of PCV712. In Calgary, Canada, the results in 
children younger than 2 years were similar: over-
all incidence of invasive pneumococcal disease 
decreased by 69.9%, and the reduction for the 
PCV7 serotypes was 88.7% 17. 
As for mortality, the current study’s results 
show a consistent drop in the number of deaths 
when comparing pre- and post-introduction of 
IMPACT OF 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE 281
Cad. Saúde Pública, Rio de Janeiro, 31(2):276-284, fev, 2015
PCV10, with a reduction in both the absolute 
number and mortality rate, especially in the 6-11 
month age group, and in the second year post-
vaccination in children younger than six months, 
representing a herd effect, as described in previ-
ous studies 21. 
The reduction in the number of deaths and 
in the mortality rate corroborate the findings by 
Hicks et al. 30 in the United States, reporting a 
decline in mortality from invasive pneumococ-
cal disease due to vaccine serotypes in children 
younger than 2 years, and other studies reporting 
reductions of 62.5% and 57.1% in overall mor-
tality from invasive pneumococcal disease in 
children eligible for vaccination 12,31. A study in 
Gambia using a 9-valent pneumococcal vaccine 
(PCV9) showed a 16% reduction in infant mortal-
ity, with similar reductions in disease shown in 
South Africa 32.
In terms of case-fatality, the current study’s 
findings corroborate those of Berezin et al. 33, 
with 20% case-fatality from pneumococcal men-
ingitis, and the results published by Menezes et 
al. 28, with a 28.6% drop in children younger than 
15 years and 41.9% in those younger than 5 years. 
Despite the observed impact on pneumococcal 
disease and even with advances in patient care, 
the case-fatality rates vary between adults 34 and 
children 35,36. For meningitis, the observed de-
crease is 16% to 37% in children and 1% to 3% in 
adults 37, consistent with the estimates of 8% and 
12% that have not changed in 20 years, despite 
progress in diagnosis and treatment 38,39.
Concerning gender, a study in the United 
States found that the proportion of cases of 
pneumococcal meningitis was higher in males 
than in females 40. In Brazil, results of different 
studies are similar 15,28,41 and consistent with the 
current study’s findings. 
The use of secondary data in epidemiologi-
cal studies can pose limitations, prone to biases, 
ranging from case capture to data entry. In addi-
tion, ecological analyses are not indicated for de-
termining causality, since other changes that oc-
cur simultaneously with introduction of the vac-
cine are not controlled and demonstrated in the 
study, thus suggesting the need for future work to 
consolidate the findings. Still, this study’s results 
provide important evidence on the impact of the 
10-valent pneumococcal conjugate vaccine in re-
ducing pneumococcal meningitis in Brazil. 
Finally, the current study’s results demon-
strate that two years after introduction of PCV10 
in Brazil there were important decreases in in-
cidence and mortality rates, highlighting the 
importance of prevention. Active surveillance 
of pneumococcal disease is necessary, with con-
tinuing evaluation of the epidemiological profile 
and pattern of circulating serotypes.
Resumen
El objetivo de este estudio fue analizar el impacto de la 
vacunación contra el Streptococcus pneumoniae en la 
morbilidad y mortalidad de la meningitis neumocócica 
en niños ≤ 2 años en Brasil, 2007-2012. Se trata de un 
estudio descriptivo ecológico que analiza los datos del 
Sistema de Información Enfermedades de Notificación 
Obligatoria en Brasil. El período previo (2007-2009) y 
posterior a la vacunación (2011-2012) fueron exami-
nados para comparar las tasas de incidencia y morta-
lidad. 1.311 casos de meningitis neumocócica con 430 
muertes se registraron durante el período de estudio. 
Hubo una disminución de la incidencia de 3,70 ca-
sos por 100.000 habitantes en 2007, a 1,84/100.000 en 
2012, mientras que la tasa de mortalidad cayó 1,30 a 
0,40 óbitos/100.000, se produjeron reducciones del 50% 
y 69%, respectivamente, con mayores impactos identifi-
cados entre los niños de 6-11 meses de edad. Los resul-
tados indican una reducción en la morbilidad y morta-
lidad por meningitis neumocócica dos años después de 
la introducción de la vacuna conjugada antineumocó-
cica 10-valente, lo que sugiere su eficacia.
Streptococcus pneumoniae; Meningitis; Vacunas
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